{"id":460636,"date":"2025-09-29T14:38:17","date_gmt":"2025-09-29T14:38:17","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/460636\/"},"modified":"2025-09-29T14:38:17","modified_gmt":"2025-09-29T14:38:17","slug":"astrazeneca-to-list-shares-in-new-york-while-keeping-london-listing","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/460636\/","title":{"rendered":"AstraZeneca to list shares in New York while keeping London listing"},"content":{"rendered":"

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45.<\/p>\n

LONDON \u2014 AstraZeneca on Monday said it planned to start listing its shares on the New York Stock Exchange while maintaining its London listing.<\/p>\n

The company said the move would allow investors in its biggest market easier access to the company\u2019s regular shares, but it will be seen as a blow to the U.K., which has witnessed a number of companies flee London listings<\/a> and move them to New York.\u00a0<\/p>\n

It also comes as pharma companies continue to criticize the U.K.<\/a> over its drug pricing policies and as a poor commercial environment<\/a> for drugmakers. AstraZeneca in particular has pulled some of its investments in the U.K. and sparred with health officials over pricing and access tied to its breast cancer drug Enhertu.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…\n","protected":false},"author":2,"featured_media":460637,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7757],"tags":[8295,748,393,4884,257,5489,31173,16,15],"class_list":{"0":"post-460636","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-london","8":"tag-astrazeneca","9":"tag-britain","10":"tag-england","11":"tag-great-britain","12":"tag-london","13":"tag-pharmaceuticals","14":"tag-stat","15":"tag-uk","16":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115288100714012945","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/460636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=460636"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/460636\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/460637"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=460636"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=460636"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=460636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}